TMCnet News
Vulvar Cancer - Pipeline Review, H2 2017 - Research and MarketsThe "Vulvar Cancer - Pipeline Review, H2 2017" report has been added to Research and Markets' offering. Vulvar Cancer - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Vulvar Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Vulvar Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Vulvar Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies Universities /Institutes, the molecules developed by Companies in Phase II and Preclinical stages are 4 and 1 respectively. Vulvar Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Key Topics Covered:
For more information about this report visit https://www.researchandmarkets.com/research/74544x/vulvar_cancer?w=4 View source version on businesswire.com: http://www.businesswire.com/news/home/20171207005888/en/ |
